ImageneBio (IMA) Receivables - Other (2024 - 2025)
ImageneBio's (IMA) quarterly Receivables - Other came in at $728000.0 in Q3 2025, up 777.11% quarter-over-quarter from $83000.0 in Q4 2024.
Powered by 
Analysis
ImageneBio (IMA) Receivables - Other (2024 - 2025) Analysis & Trends
ImageneBio has disclosed Receivables - Other across 2 years of filings, most recently posting $728000.0 for Q3 2025.
- In Q3 2025, Receivables - Other changed N/A year-over-year to $728000.0; the TTM figure through Sep 2025 stood at $728000.0 (changed N/A YoY), while the FY2024 annual figure was $83000.0, changed N/A from the prior year.
- Receivables - Other came in at $728000.0 for Q3 2025 at ImageneBio, up from $83000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $728000.0 in Q3 2025 to a low of $83000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - |